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                                                            ABSTRACT 
 
 
 
 
Penchikala Madhuri. M.S., Department of Pharmacology & Toxicology, Wright State 
University, 2007. Angiotensin AT1 Receptor Blockade Protects the Brain from Ischemic 
Damage.1 
 
 
 
 
 
1Angiotensin (Ang) AT1 receptors are considered to play an important role in ischemic 
stroke via degenerative processes leading to cell death. Recent clinical and basic studies 
show that systemic blockade of Ang AT1 receptors reduces brain lesion in ischemic 
stroke. In this study we evaluated whether blockade of central Ang AT1 receptors protects 
the brain from ischemia and inflammation during ischemic stroke. Adult male C57BL/6 
mice were divided into two groups for chronic intracerebroventricular (ICV) infusion of a 
selective Ang AT1 receptor antagonist, losartan (Los, n=18, 2 ug/hr) or isotonic saline 
(Con, n=20) using osmotic minipump. Twelve days post infusion, focal cerebral ischemia 
was induced by middle cerebral artery occlusion (MCAO). The success of MCAO was 
verified by measurement of cerebral blood flow (CBF) using laser-Doppler flowmetry. 
Neurological deficits due to ischemic damage of neuronal cells were evaluated 24 hours 
after MCAO. Brains were removed 48 hrs after MCAO and the degree of damage due to 
ischemia was determined using triphenyltetrazolium chloride (TTC) staining. The 
expression of Ang AT1 receptors, matrix metalloproteinase-2 (MMP-2) and 
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myeloperoxidase (MPO) was carried out using western blot analysis. 
Immunohistochemistry was performed to determine the inflammatory cell infiltration in 
control vs. losartan treated mice. Focal cerebral ischemia resulted in overexpression of 
Ang AT1 receptor ischemic hemisphere compared to non-ischemic hemisphere (27%, 
p<0.05) suggesting a role of Ang AT1 receptor in ischemia. We also found a significant 
increase in the expression of MPO and MMP-2 in ischemic vs. non-ischemic 
hemispheres. Pretreatment with losartan significantly improved neurological deficits and 
infarct volume compared to control mice (p < 0.05). Parelleling these effects on ischemia, 
losartan pretreatment also reduced (~50%) the reactive upregulation of MPO (P < 0.05) 
and inflammatory cells (neutrophils and macrophages, P < 0.01) in the ischemic area. 
These results support a role for Ang AT1 receptors in cerebral ischemia and inflammation 
produced by stroke. 
Key words: Stroke, angiotensin II, angiotensin type I (AT1) receptor, middle cerebral 
artery occlusion, ICV infusion, losartan 
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INTRODUCTION AND PURPOSE 
Today, stroke is the second most frequent cause of death and the most frequent cause of 
invalidity. Stroke is defined as a new-onset neurological deficit of vascular origin lasting 
24 hours or longer or until death. It can be classified into two major categories, ischemic 
& hemorrhagic; In about 80% of cases, stroke is caused by cerebral ischemia and in about 
20% by intracerebral hemorrhage, subarachnoidal hemorrhage, venous thrombosis and 
other cerebrovascular diseases. Risk factors for stroke include, i) Risks that you cannot 
control: Increasing age,  Male sex, Race, Family history of stroke and ii) Risks that can 
be controlled with Medical Treatment & Lifestyle Changes: High blood pressure, 
Tobacco use, High cholesterol, Obesity/overweight, Physical inactivity, Diabetes, Atrial 
fibrillation (irregular heartbeat) , Unhealthy diet , Cardiac disease.  Hypertension is a 
factor in nearly 70% of stroke cases (Bronner, Kanter, and Manson 1995).  
PATHOPHYSIOLOGY OF ISCHEMIC STROKE 
Ischemic stroke results from a transient or permanent reduction or interruption of 
cerebral blood flow (CBF). The normal CBF is approximately 50 to 60 ml/100gm/minute 
and varies in different parts of the brain. In response to ischemia, the cerebral 
autoregulatory mechanisms compensate for a reduction in CBF by local vasodilation, 
opening the collaterals and increasing the extraction of oxygen and glucose from the 
blood. However when the CBF is reduced to below 20 ml/100gm/minute, an electrical 
silence ensues and synaptic activity is greatly diminished in an attempt to preserve energy 
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stores. CBF of less than 10 ml/100gm/minute results in irreversible neuronal injury 
(Astrup, Siesjo, and Symon 1981; Hakim 1998; Wise et al. 1983). Stroke results in a core 
area of cell death (infarct) due to interrupted circulation, with a larger surrounding area of 
compromised cell function resulting from reduced perfusion (penumbra). 
At the molecular level, the development of hypoxic- ischemic neuronal injury is 
greatly influenced by “overreaction” of certain neurotransmitters, primarily glutamate 
and aspartate. This process called “excitotoxicity” is triggered by depletion of cellular 
energy stores. Glutamate, which is normally stored inside the synaptic terminals, is 
cleared from the extracellular space by an energy dependent process. The greatly 
increased concentration of glutamate (and aspartate) in the extracellular space in a 
depleted energy state results in the opening of calcium channels associated with N-
methy1-D-asapartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxanole 
propionate (AMPA) receptors. Persistent membrane depolarization causes influx of 
calcium, sodium, and chloride ions and efflux of potassium ions (Siesjo 1981; Siesjo, 
Agardh, and Bengtsson 1989). Intracellular calcium is responsible for activation of a 
series of destructive enzymes such as proteases, lipases, and endonucleases that allow 
release of cytokines and other mediators, resulting in the loss of cellular integrity 
(Hademenos and Massoud 1997; Siesjo 1981). 
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                  Figure 1. Pathophysiology of Ischemic brain damage at molecular level. 
The two processes by which injured neurons are known to die are coagulation 
necrosis and apoptosis. Necrosis evolves over 6-12 hrs and apoptosis develops with in 
days and weeks.  Delayed edema and inflammation lead to secondary brain damage. 
Apoptosis is probably induced by ischemia and can cause secondary deterioration 
(Kajstura et al. 1997). The outcome of stroke mostly depends on the severity of cerebral 
blood flow reduction and on the duration of the ischemic insult (Dirnagl, Iadecola, and 
Moskowitz 1999). 
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BRAIN ANG II SYSTEM 
The renin angiotensin system (RAS) is both a circulating and tissue based 
hormonal system that regulates homeostasis and tissue responses to injury. Angiotensin II 
(Ang II)) is the most important effector peptide of  the RAS and has potent effects on 
vascular tone and sympathetic transmission and on the regulation of body fluid volume. It 
also influences endothelial function and stimulates inflammatory, proliferative, fibrotic 
and thrombotic processes (Schrader, Kulschewski, and Dendorfer 2007). Ang II, initially 
described as a peripheral circulating hormone regulating systemic blood pressure and 
fluid homeostasis, was later recognized as a brain neuromodulator inducing fluid and salt 
intake and blood pressure increase through stimulation of its physiological receptors, the 
AT1 receptor type (Saavedra 2005).  
All components of the classical RAS, such as angiotensinogen, renin, angiotensin- 
converting enzyme (ACE), and Ang II are present in the brain (Ganten et al. 1984; 
Phillips and Sumners 1998; Saavedra 1992). However, localization studies have revealed 
a puzzling picture, because there is not a single brain cell where all RAS components are 
normally expressed (Fig. 1). The postulate of brain Ang II formation through a classical 
RAS system requires multiple-cell interactions at long distances, enough to make the 
system unrealistically complex and inefficient. Conversely, the selective receptor 
localization clearly demonstrates that stimulation of receptors by Ang II is likely to result 
in specific, selective effects. Alternative hypotheses are necessary to explain how brain 
Ang II is produced and how the peptide reaches its receptors at physiologically active 
concentrations (Saavedra 2005).  
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There are two closely integrated central Ang II systems, one responding to Ang II 
generated in the brain and stimulating receptors inside the blood brain barrier, another 
with Ang II receptors in circumventricular organs, cerebrovascular endothelial and 
smooth muscle cells, responding to circulating Ang II of peripheral origin, and/or to 
locally generated Ang II (Saavedra 2005). AT1 receptors located in the cerebrovascular 
endothelium and in specific brain areas participate in the regulation of cerebrovascular 
circulation. Many of the classical and hypothetical functions of brain Ang II are mediated 
by the stimulation of Ang AT1 Receptors (Saavedra 2005).          
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Figure 2: RAS in the brain. Two possible ways of Ang II generation within the CNS are 
discussed: 1) volume transmission: extracellular generation of angiotensin peptides, 
acting as neurohormones; and 2) wiring transmission: uptake of angiotensinogen by 
neurons and formation of peptides within the neuron. Ang II acts as neurotransmitter or  
cotransmitter (Paul et al. 1993).     
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SIGNIFICANCE OF ANG II IN ISCHEMIC STROKE 
The subtypes of angiotensin receptors, referred to as AT1 and AT2 receptors, are 
expressed in the brain. In the adult, the majority of brain areas express predominantly the 
AT1 receptor that mediates most of the known central actions of Ang II not only on blood 
pressure and osmo control but also on neuroplasticity (Culman et al. 2001; de Gasparo et al. 
2000). Beside its critical role in cardiovascular and fluid homeostasis, several lines of 
evidence implicate Ang II in ischemic neuronal injury. During the past decade, a number of 
studies have indicated that Ang II, the main effector peptide of renin angiotensin system, may 
be involved in the pathogenesis of cerebral ischemia (Culman et al. 2001). Maeda et al 
(Maeda et al. 1999),  showed better collateral circulation and smaller lesion size in 
angiotensinogen knockout mice than in controls 1 hr after experimental stroke, indicating a 
beneficial effect of lower Ang II levels before the onset of ischemia.Walther et al. 
demonstrated a direct correlation between brain angiotensin II and the severity of ischemic 
injury in experimental stroke (Walther et al. 2002). In this study, they proved for the first 
time that activation of AT1 receptors also initiates proapoptotic stimuli in neuronal cells. 
              There are several mechanisms by which Ang II, acting via the AT1 receptor, 
could contribute to ischemic brain damage- for example, reduction of cerebral blood flow 
(CBF), induction of inflammation, production of reactive oxygen species (ROS) with 
consecutive cell destruction, or promotion of apoptosis (de Gasparo et al. 2000; Kaschina 
and Unger 2003; Stenman and Edvinsson 2004). Apoptosis may be directly due to Ang 
II; since, in vitro studies by (Kajstura et al. 1997) showed that programmed cell death in 
cells is due to Ang II. Inflammatory mechanisms are implicated, with the accumulation of 
neutrophils and the subsequent disruption of the blood–brain barrier (BBB). In addition, 
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the development of oedema, necrosis and scar formation brings about secondary brain 
damage (Tomita and Fukuuchi 1996). The CBF is also affected, with the induction of 
hypertrophy and hyperplasia of the vascular smooth muscle and an increase in vascular 
permeability (Unger 2001). It is assumed that cerebral ischemia induces a change 
(stimulates) in local vascular Ang II receptor function, which might influence the renin 
angiotensin system and a number of Ang II - mediated mechanisms of actions that  may 
contribute to the worsening of ischemia and formation of the penumbral zone. 
 
                    
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Proposed mechanisms of angiotensin II-induced worsening of brain ischemia 
(Unger 2001). 
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ANGIOTENSIN RECEPTOR BLOCKERS IN ISCHEMIC STROKE 
Angiotensin receptor blockers (ARBs) have emerged lately as being very 
effective and perhaps superior to other antihypertensive drugs in the prevention of de 
novo or recurrent strokes. (Chrysant and Chrysant 2006). Walther et al showed that 
sustained blockade of AT1 receptors with peripheral and centrally activeAT1 receptor 
antagonists reverse the cerebrovascular pathological growth and inflammation, increases 
cerebrovascular compliance, restores the eNOS/iNOS ratio and decreases cerebrovascular 
inflammation. These effects result in a reduction of the vulnerability to brain ischemia 
(Walther et al. 2002).  
There is a good correlation between the area of blood flow below the required 
protective threshold and the area of neuronal injury and death, both significantly reduced 
by AT1 receptor blockade (Ito et al. 2002). The underlying mechanisms of the ARB effect 
include a blockade of the vasoconstrictive and pro-growth effects of Ang II. Systemic 
treatment with AT1 receptor antagonists has been reported to prevent the occurrence of 
stroke in spontaneously hypertensive rats and to reduce the degree of neuronal damage 
after ischemia in hypertensive and normotensive rats during ischemic stroke (Groth et al. 
2003; Inada et al. 1997; Ito et al. 2002; Nishimura, Ito, and Saavedra 2000; Stier et al. 
1993).   
Nishimura et al (Nishimura, Ito, and Saavedra 2000) reported that blockade of 
AT1 receptor by an ARB, candesartan, reduced the ischemic area after middle cerebral 
artery occlusion (MCAO) in genetically hypertensive rats. In the MCAO study done on 
rats, Emelie Stenman and Lars Edvinsson observed an increase in the relative amount of 
ACE mRNA in the occluded middle cerebral artery (MCA) and increased contractile AT1 
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receptor- mediated responses in the ipsilateral MCA 48 hours after MCAO, suggesting a 
locally enhanced production of Ang II after cerebral ischemia (Stenman and Edvinsson 
2004). These results support a role for AT1 receptors in cerebral ischemia, and that AT1 
receptors might be future therapeutic target in ischemic stroke . 
Losartan is an AT1 receptor antagonist that is used clinically to lower blood 
pressure but has also been shown to decrease the incidence of stroke (Forder, 
Munzenmaier, and Greene 2005). Some studies have implied that blockade of the AT1 
receptor allows for a more active angiogenic and neuroprotective role of the AT2 receptor 
in ischemic stroke (Achard et al. 2001; Shibata et al. 1998). Losartan Intervention For 
Endpoint reduction in hypertension (LIFE) study reported that a losrtan-based treatment 
reduced stroke risk more than therapy based on atenolol in patients with cardiovascular 
risk (Kjeldsen et al. 2005). However, direct evidence of how ARBs act as cerebro-
protective agents in stroke is currently lacking. Recent studies have shown that chronic, 
but not acute, pretreatment with an AT1 receptor antagonist significantly improves 
neurological outcome and reduces the infarct size after temporary middle cerebral artery 
(MCA) occlusion followed by reperfusion in normotensive rats (Groth et al. 2003; Ito, 
Nishimura, and Saavedra 2001; Ito et al. 2002).  
BRAIN ANG II AND INFLAMMATION IN ISCHEMIC STROKE 
Inflammation is a critical process after stroke (Danton and Dietrich 2003). After 
the interruption of CBF, tissue injury begins with an inflammatory reaction, which is a 
common response of the cerebral parenchyma to various forms of insult. This requires the 
infiltration of leukocytes, both PMN leukocytes and monocytes/macrophages (but not 
lymphocytes), which are the cellular mediators of subsequent microvessel obstruction, 
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edema formation, cellular necrosis, and tissue infarction (Chou et al. 2004; Clark et al. 
1993). Microglia/macrophages secrete a number of both toxic and protective effector 
molecules and thereby play a key role in inflammatory CNS processes (Schroeter et al. 
2001).  
Human data concerning the role of leukocytes in stroke includes an autopsy study  
demonstrating histologic PMN infiltration of the cerebral parenchyma 48 to 72 hours 
after stroke and evidence of radiolabeled leukocyte accumulation as early as 6 to 12 hours 
after stroke in partially perfused brain regions (Aspey et al. 1989). Taken further, 
leukocytes may be hypothesized to be the cells responsible for the progression from 
tissue ischemia to cerebral infarction (Dietrich et al. 1987; Zhang et al. 1994) 
The recruitment of leukocytes in the ischemic regions requires a sequence of 
events beginning with leukocyte rolling on the activated endothelial blood vessel walls, 
neutrophil activation, adherence to endothelial cells, and transmigration into the cerebral 
parenchyma. Stimulation of brain and cerebrovascular Ang II systems may contribute not 
only to vasoconstriction but also to increased expression of  inflammatory factors and 
increased microvessel permeability (Ito, Takemori, and Suzuki 2001).  
Matrix metalloproteinases (MMPs) are a family of zinc dependent proteases 
responsible for the extracellular matrix turnover and degradation of bioactive proteins. 
MMPs play an important role in cell death and are upregulated after focal cerebral 
ischemia (Tsubokawa et al. 2006).  The main forms of MMPs involved in the ECM 
alterations are MMP-2 and MMP-9. MMPs 2 and 9 have been shown to be elevated a few 
hours after ischemia (Gasche et al. 1999) and to maintain increased activity for days after 
the onset (Clark et al. 1997; Rosenberg et al. 1996). Animal studies revealed that early 
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increased expression of  MMP-2/ MMP-9 in endothelial cells and infiltrating neutrophils 
is a significant response to cerebral focal ischemia (Romanic et al. 1998).  
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HYPOTHESIS 
Intracerebroventricular (ICV) pretreatment with AT1 receptor antagonist 
(Losartan) protects the brain from ischemic brain damage in mice induced with focal 
cerebral ischemia. 
SPECIFIC AIMS 
1) To determine the effect of ischemic stroke on Ang AT1 receptor expression in mouse 
brain. 
2) To determine the effects of brain Ang AT 1 receptor blockade (Losartan) on ischemic 
brain damage. 
3) To explore if AT1 receptor blockade has significant role in reducing the inflammatory 
response and activation of extracellular MMP-2 after stroke. 
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EXPERIMENTAL DESIGN 
Materials and Methods. 
Animals. Strain-related differences exist regarding vulnerability to cerebral ischemia. 
The most likely reason for such strain-related difference is the presence of variations in 
the cerebrovascular anatomy. The middle cerebral artery has a larger vascular supplying 
territory in C57BL/6 (Tamaki et al. 2006) mice compared to other strains. Adult male 
C57BL/6 mice (25 to 30 g; Harlan, Indianapolis, Inc) were used for all experiments in 
this study. Mice were fed standard chow (Harlan) and water ad libitum. All procedures 
were approved by the Wright State University Laboratory Animal Care and Use 
Committee (LACUC) and were in accordance with the Guide for the Care and Use of 
Laboratory Animals issued by the National Institutes of Health.  
There are two survival surgeries in C57BL/6 mice, which are implantation of 
minipump for infusion of drugs into intracerebral ventricle (ICV) and placement of 
monofilament suture to induce focal ischemic stroke by occlusion of middle cerebral 
artery (MCAO) through carotid artery as described below.   
Animal Surgeries: For anesthesia in Survival surgeries, ketamine:xylazine mixture was 
used (100:8 mg/kg). Anesthetic state was determined by visual inspection and lack of 
response to tail pinch. Surgical areas were shaved and all procedures were performed 
aseptically.
 15
Implantation of ICV Minipump 
Mice were instrumented with ICV minipumps for chronic (2 weeks) central 
infusion of AT1 receptor specific antagonist, Losartan (2 µg/hr). Osmotic minipumps 
(ALZET Model No. 1002), which continuously deliver dissolved substances at a rate of 
0.25 µL/hr into the desired tissue area, were filled with vehicle or the AT1 receptor 
antagonist, Losartan. The flow moderator of the pump was connected with a polyethylene 
catheter to a curved (right-angled) metal cannula (30-gauge) to allow long-term ICV 
infusion of drugs. The pumps were placed in sterile saline solution (0.9%) overnight at 
37°C before implantation to initiate their operation at a constant pumping rate and to 
minimize the possibility of  occlusion or clot formation in the catheter. Head of the 
mouse was fixed in the stereotaxic apparatus, and the skull was exposed by a midline 
sagittal incision through the scalp. Then, a subcutaneous pocket was prepared at the back 
of the mouse. The osmotic pump was placed into the pocket, and the right-angled metal 
cannula was inserted through the skull into the brain (depth 3 mm) to reach the ventricle. 
The external part of the metal cannula was fixed to the skull with dental cement, and the 
wound was sutured.(Dai et al. 1999) After operation, mice were treated with 
buprenorphine (0.1 mg/kg, sc), 3 doses (36 hrs) with the first dose given immediately 
after accomplishment of the surgery. 
Middle Cerebral Artery Occlusion  
Middle cerebral artery occlusion (MCAO, Ito et al., 2002), is a common method 
used to induce ischemic stroke in rodents,  a model that results in a profound decrease in 
blood flow predominantly localized to the ipsilateral cortical areas leading to relatively 
reproducible cortical infarct volumes. Focal cerebral ischemia was induced according to 
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the procedure described by Longa et al. (Longa et al. 1989). Briefly mouse was 
anesthetized using ketamine:xylazine mixture (100:8 mg/kg). Midline skin incision was 
made along the neck. One drop of bupivicaine (0.25% bupivicaine ) was applied locally 
for anesthesia and hemostasis. Left common carotid artery was exposed by blunt 
dissection and the external carotid artery was ligated. A small incision was made on the 
dorsal side of the left common carotid artery to introduce a 7-0 nylon monofilament 
(Ethicon, Somerville, NJ, USA) treated with lysine and heat-blunted at the tip and the 
suture was advanced 10-13 mm distal to the carotid bifurcation. If left in place, this 
results in permanent MCAO and the skin incision was then sutured. The success of 
MCAO was verified by measuring the regional cerebral blow flow (CBF) using laser-
doppler flowmetry. After operation, mice were treated with buprenophine (0.1 mg/kg, sc) 
for 3 doses (36 hrs) with the first dose applied immediately after accomplishment of the 
surgery. 
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Schematic explanation of embolization and the operation 
procedure
C
                     
Figure 4: An assembled view (A) of brain and neck and an original image with skull (B) 
in normal C57BL/6J mice. ACA; anterior cerebral artery, BA; basilar artery, CCA; 
common carotid artery, ECA; external carotid artery, ICA; internal carotid artery, MCA; 
middle cerebral artery, PCA; posterior cerebral artery, PPA; pterygopalatine artery,SCA; 
superior cerebellar artery, VA; vertebral artery (Tamaki et al. 2006). Schematic 
representation of MCAO by passing a nylon monofilament through an incision on the 
common carotid artery (C). 
Measurement of  Cerebral Blood Flow 
 The regional cerebral blow flow (CBF) was measured by laser-doppler 
flowmetry (PF2B, Perimed, Stockholm, Sweden) and recorded on a data acquisition 
system (AD instruments, MA, USA).  The mouse was anesthetized using 
ketamine:xylazine mixture. An incision was made along the site for fixing the probe on 
the surface of  the brain. One drop of bupivicaine (0.25% bupivicaine ) was locally 
applied for anesthesia and hemostasis. The fiberoptic probe tip (Perimed PF 319:2, 
diameter 0.5 mm) was fixed 2 mm posterior, 3 mm lateral to bregma on the ipsilateral 
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hemisphere. This site on the convex brain surface reflects the vascular territory supplied 
by distal segments of the middle cerebral artery. CBF values were recorded before and 
after MCAO to verify the success of occlusion. 
              
Figure 5: Cerebral blood flow recorded using laser Doppler flowmetry immediately after 
middle cerebral artery occlusion (MCAO). The cerebral blood flow (CBF) dropped to 
less than 10 immediately after occlusion of the middle cerebral artery indicating the 
success of occlusion. 
Experimental protocol I (specific aims 1 & 3)  
To set up MCAO surgery with ICV minipump implantation, C57BL/6 mice were 
divided into 2 groups: Group 1) Vehicle + MCAO (ischemic stroke, n = 12), Group 2) 
AT1  receptor blocker (losartan, n = 10) + MCAO. Mice were implanted with ICV 
minipump infusion kit (Alzet 3) for chronic infusion of vehicle or losartan (2 µg/hr). 12 
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days post infusion, MCAO surgery was done by occluding left middle cerebral artery to 
induce ischemic stroke. 
                        Table 1: Overview of Experimental protocol I 
 
 
 
 
Mice were sacrificed on day 14 (48 hr after MCAO). Brains extracted were 
quickly frozen in dry ice (Western blotting) or fixed in 4% parafarmadehyde 
(Immunohistochemistry and Fluoro-jade staining) and stored at -80 o C for histological 
analysis of brain damage, inflammatory cell infiltration and protein expression.                
Experimental protocol II (specific aim 2) 
ICV minipump surgery was set up for chronic infusion of losartan (2 µg/hr)/ 
vehicle followed by MCAO surgery. Mice were divided into 2 groups (8/group): Group 
1) vehicle + MCAO stroke, Group 2) AT1 receptor blocker (losartan) + MCAO stroke.  
ICV minipump implantation surgery → ICV infusion of losartan / vehicle for 14 days → 
MCAO surgery on day 12 →  Neurological evaluation on day 13 (24 hrs after MCAO) 
sacrificed mice on day 14 (48 hrs after MCAO) . Brains extracted were sectioned 
immediately for the analysis of infarct volume. 
 
 
14Sacrifice mice
12MCAO surgery 
1-14ICV infusion of Losartan/ Vehicle
1ICV minipump implantation
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                                 Table 2: Overview of Experimental protocol II 
 
            
                                 
 
 
 
METHODS/ GENERAL PROCEDURES 
Evaluation of Neurological deficits 
The evaluation of neurological deficits was carried out 24 hours after MCAO 
according a 6-point scale: 0 = no neurological deficits, 1= failure to extend right forepaw 
fully, 2 = circling to the right, 3= falling/rolling to the right, 4 = no spontaneous walking 
with a depressed level of consciousness and 5 = death (Longa et al. 1989; Minematsu et 
al. 1992). 
Quantification of Infarct volume  
Infact volume was evaluated using 2,3,5- Tri phenyl Tetrazolium Chloride (TTC). 
TTC method is an established technique for the detection and quantification of cerebral 
infarction in experimental animals (Bederson et al. 1986). TTC is a colourless solution 
which is reduced by the enzymes of functioning mitochondria to yield a deep red 
formazan (Bederson et al. 1986). Infarcted brain regions cannot convert TTC and remain 
unstained appearing white/pale in colour. The animals that underwent the previous 
protocol were also used for quantification of  infarct volume 48 hours after MCAO i.e 
one day after neurological evaluation, mice were sacrificed. Brains were removed and cut 
14Analysis of infarct volume
13Neurological deficit evaluation
12MCAO surgery
1-14ICV infusion of Losartan/ Vehicle
1ICV minipump implantation
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into 5-6 sections of 1-mm thickness from frontal tip with a mouse brain matrix. The 
extent of ischemic infarction was revealed by reaction with a 2% solution of 2,3,5- TTC 
(Sigma Chemical, St.Louis, MO, USA) for 20-30 minutes at 37 ° C in dark (Lundy et al. 
1986). The sections were then washed with saline and fixed in 4% parafarmaldehyde for 
30 mins at room temperature. They were then stored at 4 º C in 10% formalin before 
analysis. 2,3,5-TTC is a marker for mitochondrial function and has been shown to be a 
reliable indicator of ischemic areas for up to 3 days after ischemia. Images of all stained 
slices were taken using a flat bed scanner and the border between infarct (unstained) and 
non-infarct (stained) tissue was outlined with an image analysis system(NIH, imageJ 
software). The area of infarction was measured by subtracting the area of non-lesioned 
ipsilateral hemisphere from the total area of the contralateral hemisphere (Lin et al. 
1993).  The volume of infarction was calculated by integration of lesion areas (area of 
infarct in square millimeters x thickness [1mm]). 
Fluoro-Jade Staining  
The animals were sacrificed 48 hrs after ischemic stroke and  Fluoro-Jade labeling 
was performed on brains fixed in 4% parafarmaldehyde overnight, cryo protected with 
30% sucrose in PBS for 3 days. Cryostat sections were cut at 30 µm thickness and 
collected in buffer solution which were mounted on to gelatin coated slides. Fluoro-Jade 
staining was performed by placing 30 µm coronal sections in 0.001% Fluoro-Jade 
solution (Histochem, Jefferson, AR, USA) in 0.1% acetic acid as described previously 
(Schmued and Hopkins 2000). Briefly, 30-µm mounted sections were air dried and 
rehydrated in decreasing strengths of ethanol (100 to 75%) for 3 min then distilled 
deionized water for 1 min each, then the slides were incubated in 0.06% potassium 
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permanganate, washed in distilled water, and transferred to 0.001% Fluoro-Jade staining 
solution. After staining, the sections were rinsed in distilled water, dried, immersed in 
xylene, and coverslipped with DPX (Sigma-Aldrich, St. Louis, MO, USA) to observe 
under miscroscope for histological damage. 
Western Blotting 
To determine the expression of AT1 receptor, MMP-2 and myeloperoxidase  
(MPO, marker for neutrophils) in brain tissue of mice after MCAO. The ischemic and 
non-ischemic hemispheres were separated, placed in cryotubes and flash frozen in dry 
ice. The tubes were stored in a -80 º C freezer until homogenization. Frozen tissue 
samples were homogenized in 400 µl cold Lysis buffer containing glycerol, HEPES (pH 
7.4), EDTA, NaCl, MgCl2 and protease inhibitor (Roche diagnostics, Indianapolis, IN, 
USA). The tissue was processed with a sonicator and centrifuged at 4oC for 10 minutes at 
14000 g. The supernatants were separated, frozen and kept at -80 º C until use. The total 
protein concentration was determined by Bradford method. For gel loading, the volume 
equivalent to 30 µg of total protein was loaded into fresh made 10% or 12% 
polyacrylamide gels. Gels were electrophoresed at 100V, 150 mA, 75 W until the dye 
front neared the resolving gel and then increase the voltage to 150-170 volts until the dye 
reaches bottom of the gel.  The proteins were transferred from the gel to 0.2 µm PVDF 
membranes for 2 hours at 70V, 30mA, 10W.  The PVDF membranes were blocked with 
10 ml of 10% NFDM (Carnation, Nestle) in washing buffer (0.1% Tween-20- tris- 
buffered saline, TTBS) overnight.  After washing with  wash buffer, the membranes were 
incubated overnight with either with rabbit anti mouse AT1, rabbit anti-mouse MMP-2 or 
goat anti-mouse MPO polyclonal antibody (Santa Cruz biotechnology, CA, USA) and 
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monoclonal anti-β-actin (Sigma, Saint louis, MO, USA) for actin (an internal standard). 
Membranes were washed again in TTBS, incubated with secondary antibody, goat anti-
rabbit/donkey anti-goat IgG/donkey anti-rabbit IgG, horse radish peroxidase conjugated 
antibody (Jackson ImmunoResearch Laboratories, Inc, PA, USA)  and anti-mouse actin 
(Sigma, Saint louis, MO,USA) for 1 hour. After washing with washing buffer, the sample 
proteins were visualized via the chemiluminescence produced by the ECL substrate 
(Pierce) and captured by the Fuji LAS3000 imager.  The relative amount of protein of 
interest (POI) is determined by normalizing to actin.  
Normalized Value = (POIdensity-backgrounddensity)/(actindensity-backgrounddensity)  
Immunohistochemistry 
To study the infiltration of blood borne cells (post-ischemic extravasation of 
macrophages and neutrophils which play a significant role in focal ischemia-induced 
brain damage (Hernandez et al. 1987; Zhang et al. 1994) and activation of microglia in 
order to assess the post ischemic effect of MCAO on inflammation. Brains were fixed in 
4% parafarmaldehyde overnight, cryo protected with 30% sucrose in PBS for 3 days and 
then stored at -80 º C until use. Temperature of frozen brains was resumed in a cryostat 
from -80 º C to -20 º C. 30 µm thick sections were rinsed in 0.01M PBS for 5 mins and 
incubated in blocking solution (5 % normal horse serum, Vector laboratoties, in PBS 
containing 0.3% Triton X-100 1% BSA) for 1hour at room temperature and then the 
specimens were incubated with either polyclonal goat anti-mouse MPO (Santa cruz 
biotechnology, CA, USA) or polyclonal rabbit anti-mouse CD-68 (marker for 
macrophages) antibody (Santa cruz biotechnology, CA, USA) for 2 days  at 4 º C. The 
sections were washed with PBS and incubated in biotin–conjugated horse anti-goat IgG 
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or biotin conjugated donkey anti-rabbit IgG (Vector Laboratories, CA, USA) for 1 hour 
at room temperature. After washing, the secondary antibodies were visualized by 
treatment with horseradish -conjugated avidin / biotin complex (Vector Laboratories, CA, 
USA) for 30mins-1hr at room temperature. After washing with PBS, incubated in 
diaminobenzidine/H2O2 and sections were dehydrated, mounted with permount. 
Quantification of Immuno-positive cells (Neutrophils & Macrophages)   
The distribution of neutrophils (MPO-positive cells) and Macrophages (CD-68-
positive cells) was studied at 6 levels (Figure 8 A) from 3 representative animals for each 
of control and losartan groups.  The region of pathology  from entire ipsilateral 
hemisphere of immunostained sections was photographed at four different fields using a  
Lieca DMR microscope (Leica Wetzlar, Heidelberg, Germany, 20-fold objective) and an 
Optronix magnafure digital camera system. The number of MPO and MMP-2 positive 
cells was counted in these fields (512,000 µm2, determined by NIH image J software) 
using NIH image J software (developed at the U.S. National Institutes of Health and 
available on the Internet at http://rsb.info.nih.gov/nih-image/). 
Statistical analysis 
All statistics are represented as mean ± SE. The changes in neurological scores 
were analyzed using the non-parametric Mann-whitney U-test.  The data of Infarct 
volume, Western blotting and Immunohistochemistry was assessed in treated and 
untreated mice using unpaired student’s t-test. The data of western blotting in untreated 
mice was calculated using paired student’s t-test. For all procedures, p values <0.05 were 
considered statistically significant. 
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RESULTS 
1. Effect of ischemic stroke on AT1 receptor expression 
The brain AT1 receptor expression significantly increased (p < 0.05 with paired t-test, n = 
4; Fig. 6) in the ischemic hemisphere at 48 hrs after Ischemic stroke compared to Non-
ischemic hemisphere. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Comparision of AT1 receptor expression in Non-stroke vs Stroke sides of brain 
tissue, 48 hrs after occlusion of middle cerebral artery. A) Representative gel showing an 
increased expression of AT1 receptor in Ischemic hemisphere (Stroke) compared to Non- 
ischemic hemisphere (Non-stroke). B) Densiometric analysis for AT1 receptor activity. (n 
= 4). *p < 0.05.           
Non-stroke   Stroke
AT1 Receptor
45 KDa
6 A
6 B
β-actin
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2. Effects of selective blockade of AT1 receptor on neurological deficits 
Neurological deficit evaluations were carried out 24 hours after MCAO. A scattergram of 
the neurological scores for vehicle versus losartan groups is presented in Fig. 7. Losartan 
was able to produce a significant reduction (p < 0.05; Mann Whitney U-test) in the 
neurological deficits seen in animals after ischemia when compared with vehicle-treated 
mice.  
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Scatter plots of neurological deficit scores in Vehicle versus Losartan treated 
groups evaluated 24 hrs after induction of focal cerebral ischemia. Statistical analysis was 
performed using the Mann-Whitney non parametric test. n = 6 per each group. 
 
 
 
 
P = 0.041
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3. Effect of ICV infusion of losartan on infarct volume 
Ischemia resulting from MCAO lead to brain injury of the ipsilateral hemisphere 
including cortical and subcortical areas, along with ipsilateral oedema. Mice pretreated 
with losartan showed a significant reduction in volume of injury, corrected for oedema 
compared to vehicle treated mice. The animals in vehicle-treated stroke group have  
severe neurological deficits (scores of 3, 4 and 5). These mice showed significant 
increase in lesion volume (Fig. 8A). Mice in losartan-treated stroke group, which had an 
average neurological score of 2, showed decreased lesion volume (Fig. 8B,C) . 
 
 
 
 
 
 
 
 
 
 
 
 
        
 Figure 8: One millimeter thick, 2,3,5-triphenyltetrazolium chloride (TTC) stained 
coronal sections of brain numbered from frontal (section 1) to caudal (section 6) of  
vehicle treated (A) and losartan treated (B) mice 48 hrs after MCAO. Non-ischemic areas 
had converted TTC to a deep formazan compound and appear dark in figure. Ischemic 
areas failed to metabolize TTC and appear white in figure. Note the decrease in ischemic 
area of the mice pretreated with losartan.     
8 A
8 B
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Figure 8C: Morphometry of ischemic area determined with TTC staining and expressed 
as a percentage of total area in vehicle treated vs losartan treated groups. n = 4/group. *p 
< 0.05. Values are mean ± SEM. 
4. Histological (qualitative) analysis of Ischemic brain damage due to MCAO 
Fluoro-jade staining was performed to specifically identify the success of MCAO 
and to identify the areas in brain affected by ischemic brain damage . Fluoro-Jade is an 
anionic fluorochrome capable of selectively staining degenerating neurons in brain slices. 
The histochemical application of Fluoro-Jade results in a simple, sensitive and reliable 
staining of degenerating neurons and their processes resulting from exposure to a variety 
of neurotoxic insults (Schmued, Albertson, and Slikker 1997). Fluoro-jade positive cells 
were found through out the ipsilateral cortex (Fig. 9A), caudate putamen (Fig. 9B, C), 
CAI layer and Dentate gyrus of hippocampus (Fig 9D).  
 
8C
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Figure 9: Fluoro-Jade labeling of degenerating neurons in different brain areas of 
representative ischemic mice 48 hrs after ischemia. Clusters of Fluoro-Jade-positive 
neurons amid a necrotic tissue can be observed in the cortex (A), caudate putamen (B,C), 
CAI and dentate gyrus of hippocampus (D) of vehicle treated mice. Scale bars, 100 µm.  
5. Analysis of MMP-2 and MPO expression in Vehicle versus Losartan treated 
groups. 
The brain MPO expression significantly increased (p < 0.05 with paired t-test, n = 4; Fig. 
10) in the ischemic hemisphere at 2 days after Ischemic stroke compared to non-ischemic 
hemisphere. There was also a significant increase in MMP-2 expression 48 hrs after 
 A B
C D
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MCAO in ischemic hemisphere relative to non-ischemic hemisphere (n = 4, paired t-test, 
Fig. 11). Lastly there was a reduction in the levels of MPO and MMP-2 in losartan 
pretreated mice compared to untreated (vehicle) mice (n = 4, unpaired t-test, Fig. 12). 
Though the decrease in MMP-2 expression was not significant in treated group. 
 
    
 
 
 
 
 
 
             
 
 
 
 
 
Figure 10: Comparision of MPO activity in Non-stroke vs Stroke sides 48 hrs after  
occlusion of middle cerebral artery. A) Representative gel showing an increased 
expression of MPO in Ischemic hemisphere (Stroke) compared to Non-ischemic 
hemisphere (Non-stroke). B) Densiometric analysis for MPO activity. (n = 4, *p < 0.05).  
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 Figure 11:  Comparision of MMP-2 activity in Non-stroke vs Stroke sides, 2 days after  
occlusion of middle cerebral artery. A) Representative gel showing an increase in MMP-
2 activity in Ischemic hemisphere (Stroke) compared to Non-ischemic hemisphere (Non-
stroke). B) Densiometric analysis for MMP-2 activity. (n = 4, *p < 0.05). 
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Figure 12: Chronic pretreatment with losartan reduced the ischemia-induced increase in 
MPO (80 KDa) and MMP-2 (63 KDa) expression. A) Representative gel showing the 
decreased expression of MPO and MMP-2 in mice pretreated with losartan compared to 
vehicle treated mice. B) Summary of densiometric analysis for MPO and MMP-2 activity 
(n = 4 /group). *p < 0.05 (Vehicle [MPO] vs  Losartan [MPO]). 
6. Effect of Ang II/AT1 receptor blockade on inflammatory cell infiltration 
There was a significant increase in neutrophil and macrophage infiltration in the 
ipsilateral (ischemic) hemisphere (Fig. 13 A, 14 A) compared to contralateral hemisphere 
(almost none, Fig. 13 C, 14 C) at 2 days after focal cerebral ischemia. Losartan 
pretreatment significantly reduced the inflammatory cell infiltration relative to the vehicle 
treated mice (Fig. 13 B,E and Fig. 14 B,E).          
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Figure 13:  Typical pictures of myeloperoxidase ( MPO)-positive cells (neutrophils)  in 
mice subjected to permanent occlusion of middle cerebral artery for 48 hours. 
Pictomicrographs of ipsilateral hemispheres from untreated (A), treated (B) and 
contralateral hemisphere of untreated (C) and treated groups (D, arrows indicate 
neutrophils). Scale bar = 50µm. Insert shows magnified neutrophils (63x). 
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Figure 13E: Quantification of neutrophils in Vehicle vs Losartan treated groups (E) (n = 
3/ group), **p < 0.01 (Vehicle [Ipsilateral] vs Losartan [Ip silateral]). 
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Figure 14: Typical pictures of  CD-68-positive cells (macrophages) in mice subjected to 
permanent occlusion of middle cerebral artery for 48 hours. Pictomicrographs from 
ipsilateral hemispheres of untreated (A), treated (B) and contralateral hemisphere of 
untreated (C) treated groups (D, arrows indicate macrophages). Scale bar = 50 µm. Insert 
shows magnified macrophages (63x).          
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Figure 14E: Quantification of neutrophils in Vehicle versus Losartan treated groups (E) 
(n = 3/group, ***p < 0.001). 
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DISCUSSION 
During the past decade number of studies have indicated that systemic treatment 
with AT1 receptor antagonists can prevent the occurence of stroke in spontaneously 
hypertensive rats and reduce the degree of neuronal damage and infarct volume in 
animals induced with ischemic stroke (Inada et al. 1997; Nishimura, Ito, and Saavedra 
2000; Stier et al. 1991; von Lutterotti et al. 1992). However, it is not clear whether the 
benefit is from the peripheral or central effects of AT1 receptor antagonist. For evaluating 
the role of brain AT1 receptors in ischemic stroke, we blocked these receptors by direct 
infusion of losartan into brain. The present study demonstrates that blockade of central 
AT1 receptors can protect the brain from focal cerebral ischemic damage by reducing the 
neurological outcome, extent of infarction and inflammation in normotensive mice.   
In this study, we firstly determined the Ang AT1 receptor expression after 
ischemic stroke. For the first time we showed that experimental stroke results in a 
significant upregulation of AT1 receptors in the ischemic (ipsilateral) hemisphere 
compared to non-ischemic (contralateral) hemisphere (Fig. 7) of normotensive mice. 
Upregualtion of AT1 receptor expression during ischemic phase provides the evidence of 
activated Ang II/AT1 signaling pathway in contributing to brain injury during ischemic 
stroke. Ang II AT1 receptors mediate all of the known physiological effects of Ang II in 
the central nervous system and the periphery (Saavedra 1992; Timmermans et al. 1993). 
The AT1 receptors are broadly distributed in the brain with high concentrations in the 
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forebrain, including hypothalamic nuclei and circumventricular organs (Hauser, Johren, 
and Saavedra 1998). Most of the brain Ang II receptors are localized in neurons, (Lind, 
Swanson, and Ganten 1985; Tsutsumi and Saavedra 1991) endothelial cells lining the 
cerebral vasculatures (Ando et al. 2004). The Ang II receptors in the circumventricular 
organs and cerebrovascular endothelial cells can respond to circulating Ang II; receptors 
located inside the blood barrier are activated by Ang II formed in the brain and/or 
transported to the brain from the circulation. In the current study, we determined the 
expression level of AT1 receptor only in the whole brain tissue using western blotting 
technique. Further investigation is required to see in which components (neuron, glia, 
cerebral blood vessel) of brain, the AT1 receptors are unregulated during ischemic stroke.       
Following the finding that AT1 receptors are upregulated in stroke, we tested if 
the blockade of AT1 receptors can influence (reduce) the ischemia induced damage to 
brain. For specifically targeting the brain AT1 receptors, losartan was used to inhibit these 
receptors through ICV minipump infusion. Losartan is a high affinity, nonpeptide and a 
non-competitive receptor antagonist (Lucius et al. 1999). To reach an efficient, steady-
state inhibition of central AT1 receptors at the time point of MCAO, losartan was infused 
over a 14-day period. Results showed that chronic blockade of brain AT1 receptors with 
losartan resulted in improvement of neurological deficits (Fig. 7) and reduced infarct 
volume (Fig. 8) compared with untreated animals that received the same surgical 
intervention. This constructive outcome after MCAO is supported by the reports of 
Maeda et al. (Maeda et al. 1999), who showed improved collateral circulation and smaller 
lesion size 1 hour after MCAO in angiotensinogen knockout mice than in controls, 
indicating a beneficial effect of lower Ang II levels before the onset of ischemia. Walther 
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et al. demonstrated a direct correlation between brain Ang II and the severity of ischemic 
injury in experimental stroke. This study revealed an enlarged infarct size in brain tissue 
24 hours after MCAO in angiotensinogen-overexpressing mice compared to the wild type 
mice and a smaller lesion area in AT1 knockout mice compared to wild type. They also 
demonstrated reduced cell damage in the neurons from AT1 knock out mice. This data 
provides clear evidence that neuroprotection against ischemia/hypoxia can be achieved 
by a drug- as well as a transgene-induced suppression of AT1 receptor function in vivo 
and in vitro (Walther et al. 2002). Comparable evidence of improved neurological 
outcome and infarct volume has been obtained by pharmacological blockade of Ang II 
synthesis or the AT1 receptors in hypertensive or normotenisve rats (Dai et al. 1999; 
Mark and Davis 2000; Nishimura, Ito, and Saavedra 2000; Werner et al. 1991; Yabuuchi 
et al. 1999). Losartan intervention for endpoint reduction in hypertension (LIFE) showed 
that a 25% stroke reduction in severely hypertensive patients with left ventricular 
hypertrophy treated with a losartan-based regimen compared to atenolol-based regimen. 
In a substudy of LIFE, patients with systolic hypertension showed 40% reduction in 
stroke risk with losartan. These results suggest AT1 receptor blockers contributing to 
beneficial outcome of stroke by mechanisms other than blood pressure reduction 
(Chrysant 2004; Dahlof et al. 2002) .   
In this study, we used two different staining techniques to evaluate the brain 
damage after MCAO. TTC staining was used as a quantitative method to compare the 
severity of ischemic stroke between treated and untreated groups (Fig. 8) where as 
Fluoro-jade staining was used to determine the histochemical localization of neuronal 
degeneration (Fig. 9). TTC method is an established technique for the detection and 
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quantification of cerebral infarction in experimental animals (Bederson et al. 1986). TTC 
is a marker for mitochondrial function and has been shown to be a reliable indicator of 
ischemic areas for up to 3 days after ischemia. Fluoro-Jade stains the cell bodies, 
dendrites, axons and axon terminals of degenerating neurons but does not stain healthy 
neurons, myelin, vascular elements or neuropil (Schmued, Albertson, and Slikker 1997). 
Fluoro-jade staining revealed that unilateral occlusion of middle cerebral artery in mice 
induced neuronal necrosis in the frontal and sensorimotor cortices, caudate-putamen 
region and hippocampus (Fig. 9) that coincide with behavioral impairments. These 
ischemia induced changes and functional impairments closely resemble those observed 
after focal MCAO in humans, which is the most common cause of ischemic stroke (Dai 
et al. 1999).  
Inflammation is thought to play an important role in the pathogenesis of cerebral 
ischemia and secondary damage (Danton and Dietrich 2003; Dirnagl, Iadecola, and 
Moskowitz 1999). As mentioned earlier, interruption of cerebral blood flow (CBF) leads 
to tissue injury followed by inflammatory reaction, which is a common response of the 
cerebral parenchyma to various forms of insult. This requires the infiltration of 
leukocytes, both PMN leukocytes and monocytes/macrophages (but not lymphocytes), 
which are the cellular mediators of subsequent microvessel obstruction, edema formation, 
cellular necrosis, and tissue infarction (Chou et al. 2004; Clark et al. 1993). Microglia 
/macrophages  secrete a number of both toxic and protective effector molecules and 
thereby play a key role in inflammatory CNS processes (Schroeter et al. 2001). Ito et al. 
showed that stimulation of brain and cerebrovascular Ang II systems may contribute not 
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only to vasoconstriction but also to increased expression of  inflammatory factors and 
increased microvessel permeability (Ito, Takemori, and Suzuki 2001) 
To explore if losartan has beneficial effect on inflammatory response after 
MCAO, we measured the neutrophil and macrophage infiltration in treated vs untreated 
groups. We found that ischemic stroke induced a remarkable increase in neutrophil and 
macrophage infiltration as evidenced by the expression of MPO, marker for neutrophils 
(Fig. 10, Fig. 13 A) and CD-68, marker for macrophages (Fig. 14 A) in the ipsilateral 
hemisphere. Interestingly, the inflammatory cell infiltration (neutrophils and 
macrophages) was significantly reduced (Fig 12; 13 B,E; 14 B,E) in the losartan treated 
group. The data suggests that the reduction of inflammatory response to ischemic stroke 
can, at least partly, account for the beneficial effect of the central AT1 receptor blockade 
during cerebral ischemia.  
  Earlier, Ang II has been reported to be a potent stimulator of the expression of 
matrix metalloproteinases (MMPs), which degrade the basal lamina constituents (Arenas 
et al. 2004). The potential of Ang II to increase cerebral edema can be mediated by the 
expression of MMPs. MMP-2 participates in the breakdown of collagen type IV, a major 
component of subendothelail basement membrane (Libby and Lee 2000; Sternlicht and 
Werb 2001). Moreover it has been reported (Fernandez-Patron, Radomski, and Davidge 
1999; Fernandez-Patron et al. 2000) that MMP-2 may also lead to vasoconstriction and 
inflammation through the cleavage of endothelium derived peptides. Besides an increase 
in inflammatory cell infiltration, we also found a significant increase in MMP-2 
expression during ischemic stroke. There was a significant increase in the expression of 
MMP-2 in the ischemic (ipsilateral) hemisphere compared to non-ischemic (contralateral) 
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hemisphere (Fig. 11) and losartan pretreatment reduced this ischemia induced over-
expression of MMP-2 in the ipsilateral hemisphere. But the results were not significant 
(Fig. 12). This might be related to losartan treatment and needs to be further verified by 
infusing the animals with losartan for more than 48 hrs after inducing ischemic stroke 
(MCAO) or by treating the animals with losartan more than 14 days before inducing 
ischemic stroke. Inflammation and extracellular matrix damage (MMP-2), are thought to 
play an important role in the disruption of BBB, oedema, necrosis, scar formation leading 
to secondary brain damage and apoptosis.  
AT1 receptor stimulation also initiates a cascade of signaling events, resulting in 
the phosphorylation of constitutive transcription factors which regulate the transcription 
of inducible transcription factors (ITFs), such as c-Fos and c-Jun which act as 
transcription factors for other genes (Blume, Herdegen, and Unger 1999) leading to 
apoptosis. ITFs trigger the expression of a number of proinflammatory factors in injured 
neurons, glial cells, and adhesion molecules on the endothelial cell surface (Blume, 
Herdegen, and Unger 1999). Moreover Ang II via its AT1 receptors was reported to 
enhance neutrophil accumulation via neutrophil chemoattractant factors released from 
vascular endothelial cells (Herdegen, Skene, and Bahr 1997). Therefore, a suppression of 
inflammatory reaction with reduction of ITFs and inflammatory infiltrates after the 
blockade of brain AT1 receptors may also contribute to the improved neurological 
outcome in cerebral ischemia (Thone-Reineke et al. 2004)  
BBB, which is formed by the endothelial cells that line cerebral microvessels, has 
an important role in maintaining a precisely regulated micro-environment for reliable 
neuronal signaling. At present, there is great interest in the association of brain 
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microvessels, astrocytes and neurons to form functional 'neurovascular units', and recent 
studies have highlighted the importance of brain endothelial cells in this modular 
organization (Abbott, Ronnback, and Hansson 2006). It is assumed that ischemia induces 
local AT1 receptor activation in endothelial cells/ neurons and leads to Ang II mediated 
multiple mechanisms which might contribute to generation of reactive oxygen species & 
membrane disruption, inflammation, increased expression of MMPs which lead to 
disruption of basal lamina and BBB. This might lead to leakage of various cellular and 
pathological constituents which can affect the associated astrocytes and neurons leading 
to secondary damage. An understanding of how these interactions are disturbed in 
pathological conditions and how these mechanisms are affected by inhibition of central 
AT1 receptors could lead to the development of new protective and restorative therapies.  
Long-term blockade of AT1 receptors might result in Ang II accumulation which 
may lead to enhanced interface of Ang II with AT2 receptors. Stimulation of AT2 
receptors was proposed to result in vasodilatation (NO-dependent or bradykinin-
dependent) of existing vessels and inhibition of growth, balancing AT1 receptor effects 
(Carey 2005). AT2 receptors have been implicated in the process of wound healing and 
tissue repair and increased tissue AT2 levels have been reported as early as 24 h after 
brain injury (Kimura, Sumners, and Phillips 1992; Nakajima et al. 1995; Nio et al. 1995; 
Lucius et al. 1999; Viswanathan et al. 1994). Hamai et al. showed that pretreatment with 
ARB, candesartan resulted in increased expression of AT2 receptor in the ischemic area, 
3 hours after MCAO in C57BL/6J mice (Hamai et al. 2006). So relative stimulation of 
AT2 receptor signaling by ARB treatment could have a therapeutic advantage to prevent 
neurological disorders and tissue damage after stroke. However in accordance with 
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numerous studies on ischemic stroke, direct evidence is currently lacking and needs 
further investigation to prove this hypothesis.  
Recent evidence comes from the study of  Forder et al. (Forder, Munzenmaier, 
and Greene 2005) on normotenisve rats which provides direct evidence of increased 
angiogenesis by increased microvascular measures of vessel density, increased surface 
vascularization, and maintained microvascular delivery resulting in increased 
collateralization in the cerebral vascular network ensuing little or no visible infarct after 
chronic administration of losartan followed by permanent focal ischemia on middle 
cerebral artery. Inhibition of oxidative stress may also play an important role in brain 
protection caused by ARBs in cerebral ischemia. It has been previously reported that 
brain ischemia results in increased oxidative stress due to generation of ROS (Dzau 2001; 
Laursen et al. 1997; Ushio-Fukai et al. 1996). Hamai et al. found an increase in 
superoxide production in the cerebral cortex including neurons and glial cells and in 
small arteries in the brain of C57BL/6J mice and this was found to be inhibited in the 
brain arterial wall as well as in cerebral cortex by ARB treatment (Hamai et al. 2006). 
The protection from ARBs against oxidative stress might contribute to neuroprotection 
and decreased vessel damage which protect against cerebral ischemia.  
Our current data on AT1 receptor expression, infarct volume, neurological 
deficits, inflammatory cell infiltration and MMP-2 expression combining with previous 
studies support the idea that Ang II/AT1 receptor activation is involved in the worsening 
of ischemic brain damage and inhibition of central AT1 receptors might have a potential 
role in reducing the brain damage by directly targeting the receptors at the site of original 
damage. 
 45
CONCLUSION 
 
These results strongly suggest that inhibition of central angiotensin AT1 receptors 
can protect the brain from ischemic damage and AT1 receptor blockers could be used as  
a possible novel therapy of inflammatory conditions in ischemic stroke to complement 
the traditional antithrombotic drugs and surgical procedures.  
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